Three‐yr safety and efficacy of everolimus and low‐dose cyclosporine in de novo pediatric kidney transplant patients. (June 2014)

• Record Type: Journal Article
• Authors: Ferraresso, Mariano; Belingheri, Mirco; Ginevri, Fabrizio; Murer, Luisa; Dello Strologo, Luca; Cardillo, Massimo; Parodi, Angelica; Ghirardo, Giulia; Guzzo, Isabella; Innocente, Annalisa; Ghio, Luciana
• Is Part Of: Pediatric transplantation. Volume 18:Number 4(2014:Jun.)
• Page Start: 350
• Page End: 356
• Publication Date: 2014-06
• Subjects: Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12261
• Languages: English
• ISSNs: 1397-3142

Abstract

<abstract abstract-type="main" id="petr12261-abs-0001"> <title>Abstract</title> <p>The three yr results of a multicenter trial in <italic>de novo</italic> pediatric KT treated with a proliferative signal inhibitor and low dose CNI are presented. Thirty‐seven children (9.1 ± 5 yr old) received basiliximab, cyclosporine A (CyA C2:1400 ng/mL), (MMF C0:1.5–3 μg/mL), and prednisone. Three wk later everolimus was started (C0:5–10 ng/mL), CyA was reduced (C2:600 ng/mL after 90 days 300 ng/mL), and MMF discontinued. During the three‐yr period patient and graft survivals were 96%. One patient died for causes unrelated to the immunosuppression. Cumulative acute rejection rate including protocol and indication biopsies was 21.9%. None of the patients had signs of chronic humoral rejection. Incidence of dnDSA was 5%, 11%, and 22% at one, two, and three yr post‐transplant, respectively. Mean glomerular filtration rate measured at one yr and three yr post‐transplant was 105.5 ± 31 and 110.7 ± 27 mL/min/1.73 m², respectively. A growth velocity of 7.7 ± 6.7 cm/yr was achieved with positive catch‐up growth. No malignancy or post‐transplant lymphoproliferative diseases were diagnosed. In conclusion, the treatment based on basiliximab induction, everolimus, low‐dose cyclosporine, and low‐dose prednisone leads to good long‐term efficacy in <italic>de novo</italic> pediatric KT recipients.</p> </abstract>